Search Results - "Bellin, Richard"

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer by Faivre, Emily J., McDaniel, Keith F., Albert, Daniel H., Mantena, Srinivasa R., Plotnik, Joshua P., Wilcox, Denise, Zhang, Lu, Bui, Mai H., Sheppard, George S., Wang, Le, Sehgal, Vasudha, Lin, Xiaoyu, Huang, Xiaoli, Lu, Xin, Uziel, Tamar, Hessler, Paul, Lam, Lloyd T., Bellin, Richard J., Mehta, Gaurav, Fidanze, Steve, Pratt, John K., Liu, Dachun, Hasvold, Lisa A., Sun, Chaohong, Panchal, Sanjay C., Nicolette, John J., Fossey, Stacey L., Park, Chang H., Longenecker, Kenton, Bigelow, Lance, Torrent, Maricel, Rosenberg, Saul H., Kati, Warren M., Shen, Yu

“…Proteins of the bromodomain and extra-terminal (BET) domain family are epigenetic readers that bind acetylated histones through their bromodomains to regulate…”
Get full text

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors by Lam, Lloyd T, Lin, Xiaoyu, Faivre, Emily J, Yang, Ziping, Huang, Xiaoli, Wilcox, Denise M, Bellin, Richard J, Jin, Sha, Tahir, Stephen K, Mitten, Michael, Magoc, Terry, Bhathena, Anahita, Kati, Warren M, Albert, Daniel H, Shen, Yu, Uziel, Tamar

“…Ten percent to 15% of all lung cancers are small-cell lung cancer (SCLC). SCLC usually grows and metastasizes before it is diagnosed and relapses rapidly upon…”
Get full text

Statins enhance efficacy of venetoclax in blood cancers by Lee, J Scott, Roberts, Andrew, Juarez, Dennis, Vo, Thanh-Trang T, Bhatt, Shruti, Herzog, Lee-Or, Mallya, Sharmila, Bellin, Richard J, Agarwal, Suresh K, Salem, Ahmed Hamed, Xu, Tu, Jia, Jia, Li, Lingxiao, Hanna, John R, Davids, Matthew S, Fleischman, Angela G, O'Brien, Susan, Lam, Lloyd T, Leverson, Joel D, Letai, Anthony, Schatz, Jonathan H, Fruman, David A

“…Statins have shown promise as anticancer agents in experimental and epidemiologic research. However, any benefit that they provide is likely context-dependent,…”
Get more information

Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia by Zhang, Lu, Cai, Tianyu, Lin, Xiaoyu, Huang, Xiaoli, Bui, Mai H, Plotnik, Joshua P, Bellin, Richard J, Faivre, Emily J, Kuruvilla, Vinitha M, Lam, Lloyd T, Lu, Xin, Zha, Zheng, Feng, Weiguo, Hessler, Paul, Uziel, Tamar, Zhang, Qi, Cavazos, Antonio, Han, Lina, Ferguson, Debra C, Mehta, Gaurav, Shanmugavelandy, Sriram S, Magoc, Terrance J, Rowe, Jenny, Goodwin, Neal C, Dorritie, Kathleen A, Boyiadzis, Michael, Albert, Daniel H, McDaniel, Keith F, Kati, Warren M, Konopleva, Marina, Shen, Yu

“…Dual bromodomain BET inhibitors that bind with similar affinities to the first and second bromodomains across BRD2, BRD3, BRD4, and BRDT have displayed modest…”
Get full text

Abstract 3812: JAK2 and PTPN11 mutations as potential biomarkers for BCL-xL inhibition as monotherapy and in combination therapy for acute myeloid leukemia by Bellin, Richard J., Hilgenberg, Valerie, Popovic, Relja, Uziel, Tamar, Lam, Lloyd T.

“…Acute Myeloid Leukemia (AML) is a heterogeneous disease where many distinct functional mutations have been identified. While mutations in FLT3, NRAS, NPM1, and…”
Get full text

Do Statins Enhance the Anti-Cancer Activity of Venetoclax? by Roberts, Andrew W., Xu, Tu, Jia, Jia, Agarwal, Suresh, Salem, Ahmed Hamed, Bellin, Richard J., Lam, Lloyd T., Leverson, Joel D.

“…▪ Introduction: Venetoclax is an oral, small-molecule BCL-2 inhibitor capable of restoring apoptosis in susceptible cancers. It is approved in the US for…”
Get full text

Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia by Lin, Xiaoyu, Huang, Xiaoli, Bellin, Richard, Faivre, Emily, Hessler, Paul, Lam, Lloyd, Bui, Mai Ha, Wilcox, Denise, Uziel, Tamar, Ferguson, Debra C., Magoc, Terrance J., Albert, Daniel H., McDaniel, Keith F., Kati, Warren, Shen, Yu

“…Many small-molecule inhibitors that target both bromodomains of the BET family proteins (pan BET inhibitors) are undergoing studies in clinical trials…”
Get full text